Venlo, the Netherlands, April 24, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for...
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date...
Venlo, the Netherlands, April 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of new products to further enhance cancer research as well...
Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6...
Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel...
Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel...
QIAGEN announces Form 20-F annual report filing for 2023 results
Venlo, the Netherlands, and Redwood City, California, Feb. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAGEN Biomedical KB-AI, a...
Venlo, the Netherlands, Feb. 15, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced two significant achievements in sustainability through recognitions by My...
Venlo, the Netherlands, Feb. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2023. Net sales results...